BridgeMD
Simvastatin in the Prevention of Recurrent Pancreatitis, a Triple Blind, Randomized Controlled Trial.
EU CTIS ID: 2024-513188-17-03
What this study is testing
Hypothesis: The consumption of simvastatin is associated to a lower incidence of new episodes of RP Main aim: to compare the incidence of new episodes of AP in patients with RP consuming simvastatin vs placebo.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult (>=18) patients
- At least 2 episodes of AP or episodes of chronic pancreatitis
- Written consent to participate in the study
You likely can't join if
- <2 episodes of Pancreatitis in the last 12 months.
- Abstinence syndrome due to alcohol or drugs and/or delirium tremens in the last 6 months before recruitment
- Previous (last year) failure to attend follow-up medical visits, social problems that may be associated to failure to take the medication or to perform an adequate follow-up
- Statin consumption in the previous year.
- Contraindications to the use of Statins.
- Cholelithiasis or choledocholitiasis diagnosed in the last episode of Pancreatitis.
See the full eligibility criteria
- Adult (>=18) patients
- At least 2 episodes of AP or episodes of chronic pancreatitis
- Written consent to participate in the study
- <2 episodes of Pancreatitis in the last 12 months.
- Abstinence syndrome due to alcohol or drugs and/or delirium tremens in the last 6 months before recruitment
- Previous (last year) failure to attend follow-up medical visits, social problems that may be associated to failure to take the medication or to perform an adequate follow-up
- Statin consumption in the previous year.
- Contraindications to the use of Statins.
- Cholelithiasis or choledocholitiasis diagnosed in the last episode of Pancreatitis.
- Endoscopic sphyncterotomy and/or cholecystectomy and/or pancreatic surgery between last episode of AP and recruitment or patients who are expected to undergo one of this techniques in less than a year.
- Serum triglycerides >500 mg/dL without previous specific treatment before the last episode of Pancreatitis, or in patients expected to have a change in their specific hypertriglyceridemia treatment in less than 1 year
- Primary hyperparathyroidism that has been operated between last episode of Pancreatitis and recruitment or will be operated in less than 1 year
- Autoimmune pancreatitis
- Iatrogenic Pancreatitis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.